相关实验视频

Updated: May 16, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

第四代EGFR-TKI克服C797S突变:过去,现在和未来

Die Zhang¹, Jumei Zhao¹, Yue Yang¹

¹School of Medicine, Yan'an University, Yan'an City, China.

Journal of enzyme inhibition and medicinal chemistry

|April 2, 2025

概括

第四代EGFRTKI正在出现,用于打击非小细胞肺癌 (NSCLC) 治疗中的耐药性. 这些新型抑制剂向特定的EGFR突变,为抗抗性瘤提供了新的希望.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

表皮生长因子受体 (EGFR) 的过度激活驱动各种癌症,特别是非小细胞肺癌 (NSCLC).
第一到第三代EGFR氨酸激酶抑制剂 (TKI) 显示出有效性,但由于新兴的耐药性而面临挑战.
EGFR中的C797S突变是对现有的TKI耐药性的关键机制.

研究的目的:

审查第四代EGFR-TKI的开发和治疗潜力.
分析这些新型抑制剂的设计,临床前和临床进展.
为克服EGFR-TKI耐药性的未来方向提供见解.

主要方法:

关于第四代EGFR-TKI的综合文献综述.
临床前数据的分析 (体外和体外抗瘤活性).
对药物动力学特征,结合方式和临床试验结果的评估.

主要成果:

第四代EGFR-TKI的设计是专门针对EGFR突变,包括C797S耐药性突变.
这些抑制剂在临床前和早期临床研究中显示出有前途的抗瘤活性和改善的安全性.
了解结合模式和药理动力学对于优化疗效和控制耐药性至关重要.

结论:

第四代EGFR-TKI代表了NSCLC治疗的重大进步,解决了对前一代的耐药性.
对它们的设计,临床应用和抵抗机制的持续研究是必不可少的.
这些抑制剂有望改善EGFR突变NSCLC患者的治疗结果,特别是那些具有耐药性突变的患者.

关键词:

在 EGFRC797S 突变和三重突变中.它具有抗瘤活性.这是第四代EGFR-TKI.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.